Market news

Detailed price information for Alvotech (ALVO-Q) from The Globe and Mail including charting and trades.

Alvotech (NASDAQ:ALVO) shares gained 5. 6% in premarket trading after Barclays upgraded the biosimilar drug developer from Underweight to Overweight and raised its price target from $4.

REYKJAVIK, Iceland, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) prefilled syringe and autoinjector for subcutaneous administration. Under a partne

(Updates to add share movement in the headline and the first paragraph.) Alvotech's (ALVO) shares

Alvotech stock has fallen about 50% over the past three years, yet the valuation checks currently lean cheap and the market is reacting positively to fresh licensing deals and regulatory progress. Over the past three years the share price is down about 50%, which means any case for owning Alvotech today rests heavily on a potential recovery from a deep drawdown. A recent licensing agreement with Lotus Pharmaceutical for two biosimilars and ongoing work toward U.S. approvals can support...

In August 2026, Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for biosimilar candidates AVT34 (Imfinzi) and AVT87 (Hemlibra) across the United States and eight Asian markets, with potential consideration of up to approximately US$150 million plus ongoing supply revenues. The deal expands Alvotech’s access to oncology and hematology markets while keeping it in control of development, regulatory approvals, and global product supply. We’ll now examine...

A major Wall Street firm says a regulatory shift and coming launches could change the setup for one biosimilar developer.

REYKJAVIK, Iceland, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Robert Wessman, Founder and Chairman, and Dr. Balaji V. Prasad, Chief Strategy Officer, will participate in the upcoming investor conferences in September as follows: Morgan Stanley 24th Annual Global Healthcare Conference in New York – Fireside chat on Tuesday,

Alvotech (NASDAQ:ALVO) extended its winning streak to a 5th consecutive day on Monday, jumping 18.51 percent to finish at $5.25 apiece, after the Bank of America (BofA) raised its price target for the company. In its recent coverage, BofA initiated a buy recommendation on Alvotech shares with a price target of $7, amid the closure […]

Alvotech (ALVO) stock jumps 18% as earnings, a new licensing deal and resolved FDA issues lift sentiment; see key numbers and Q4 2026 catalysts—read now.

Investing.com -- BofA Securities initiated coverage of Alvotech S.A. with a “buy” rating and a $7 price objective, versus the stock’s $4.43 price as of Monday, after the FDA’s closure of its inspection of the company’s Reykjavik manufacturing facility removed a key regulatory overhang and as the biosimilar developer enters what BofA called its most meaningful launch cycle since inception.

Alvotech's (ALVO) Q4 approval and launch timelines remain intact, with upcoming approval and launch

Alvotech (ALVO) has an average rating of overweight and mean price target of $6.47, according to ana

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

REYKJAVIK, ICELAND (August 21, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech’s candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi® (durvalumab), and AVT87, a proposed biosimilar to H

Alvotech (ALVO) has signed a licensing and commercialization agreement with Lotus Pharmaceutical for

Tipranks Press Release.

Alvotech (NASDAQ:ALVO) said its first-half 2026 results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site, while management reaffirmed full-year revenue and adjusted EBITDA guidance and highlighted upcoming regulatory decisions and pr

Moby summary of Alvotech's Q2 2026 earnings call

Alvotech (ALVO) delivered earnings and revenue surprises of -83.33% and +6.72%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

REYKJAVIK, Iceland, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the first half of 2026 and provided a business update. A supplemental long‑form earnings release and management presentation providing additional details and business update is available on our website: https://alvot

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

REYKJAVIK, Iceland, July 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has closed its inspection of the company’s manufacturing facility in Reykjavik, Iceland, conducted in May 2026. The FDA has confirmed the inspection classification of the manufacturing site is Voluntary